Suzy Madar is a Partner in the Dispute Resolution group in the Sydney office of King & Wood Mallesons. Suzy specialises in corporate, commercial and regulatory disputes with a particular focus on intellectual property and healthcare.
She has experience working on disputes across a broad range of technology, including IT, biotechnology, pharmaceuticals, food products, medical devices and industrial inventions. In particular, she has expertise advising on the regulation of therapeutic products and public health issues in Australia (including Covid-19).
Suzy has broad experience advising clients on the enforcement of intellectual property rights and defending allegations of infringement, as well as advising on commercial issues relating to intellectual property. She has represented clients in the Federal Court, Supreme Court and High Court as well as in Patent Office proceedings.
Suzy also provides advice in relation to transactions involving the transfer of intellectual property and pharmaceutical products.
- Department of Agriculture, Water and the Environment (DAWE) – acting for DAWE in relation to proceedings filed by Gold Coast Marine Aquaculture relating to an outbreak of prawn white spot disease in Australia.
- Confidential Client – acting for a confidential client in relation to a substantial regulatory request to produce documents.
- FMC Corporation – acts for leading agricultural sciences company in relation to the enforcement of patent rights and the regulation of pesticides and veterinary products in Australia.
- Confidential Client – acts for a public department in relation to action taken in respect of the Ruby Princess in the COVID-19 crisis.
- Consumer Health Products Australia (CHP) – advises CHP in relation to the regulatory landscape that applies to advertising of therapeutic products.
- Laser Clinics Australia – advises Laser Clinics Australia in relation to the regulation of therapeutic and cosmetic products and services in Australia.
- New Payments Platform – provides patent infringement and validity advice to the New Payments Platform.
- Acts for several clients in relation to therapeutic products used in the prevention and treatment of COVID-19 as well as compliance with regulations directed to the COVID-19 pandemic.
- Alphapharm (Mylan) v Wyeth – acted for Alphapharm to revoke a Wyeth patent relating to a drug used in the treatment of depression. Also acted to claim compensation for Mylan having been kept out of the market.
- Confidential Client – acted for a confidential client in relation to infringement of a patent relating to a recombinant protein used in the treatment of blood disorders.
- Acted for China Huarong Macau Investment Holdings in a cross-border dispute relating to corporate law issues, including directors' duties and governance issues.
- Acts for Aspen Pharmacare on a range of commercial agreements and disputes relating to therapeutic products.
- Advises Pulmonx Corporation in relation to the regulation of medical devices and clinical trials in Australia.
- Caltex v FleetCor – acted for FleetCor in proceedings relating to a large contractual dispute over the supply of a software platform.
- Dometic – acted for Dometic Australia and Dometic Sweden in proceedings concerning a patent relating to an air conditioning unit used in recreational vehicles.
- Mylan, Aspen, Apotex – acted for Mylan, Aspen and Apotex in relation to the validity, infringement and extension of term of a patent (as well as an extension of time in which to apply for an extension of term) relating to a drug used in the treatment of depression.
- Acts for a range of clients in relation to acquisitions and restructuring of Australian assets in the healthcare space.
- 2002: Bachelor of Science, University of Sydney
- 2005: Bachelor of Laws (First Class Honours), University of Sydney
- 2006: Solicitor, King & Wood Mallesons
- 2010 – July 2019: Senior Associate, King & Wood Mallesons
- July 2019 – present: Partner, King & Wood Mallesons